

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/019,032	03/20/2002	Hai(NMN) Ye	AA484F	5117
27746	7590 11/07/2002			
THE PROCTER & GAMBLE COMPANY PATENT DIVISION HEALTH CARE RESEARCH CENTER 8340 MASON-MONTGOMERY ROAD			EXAMINER	
			ROSE, SHEP K	
MASON, OH		DAD	ART UNIT	PAPER NUMBER
•			1614	

DATE MAILED: 11/07/2002

Please find below and/or attached an Office communication concerning this application or proceeding.



Office Action Summary

Application No. 10/019 032	App ant(s)	etal	
Examiner R	ole_	Group Art Unit	

—The MAILING DATE of this communication appears on the cover sheet beneath the correspondence address— **Period for Reply** A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, such period shall, by default, expire SIX (6) MONTHS from the mailing date of this communication . - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). **Status** ☐ Responsive to communication(s) filed on ______ ☐ This action is FINAL. ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 1 1; 453 O.G. 213. Disposition of Claims 1028 is/are pending in the application. d Claim(s) _____ Of the above claim(s) is/are withdrawn from consideration. _____is/are allowed. ☐ Claim(s)_____ 1028 is/are rejected. Z Claim(s)_____ □ Claim(s) is/are objected to. requirement. **Application Papers** ☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948. ☐ The proposed drawing correction, filed on ______ is ☐ approved ☐ disapproved. ☐ The drawing(s) filed on______ is/are objected to by the Examiner. ☐ The specification is objected to by the Examiner. ☐ The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 (a)-(d) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 11 9(a)-(d). ☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been ☐ received. ☐ received in Application No. (Series Code/Serial Number) ☐ received in this national stage application from the International Bureau (PCT Rule 1 7.2(a)). *Certified copies not received:____ Attachment(s) ☑ Information Disclosure Statement(s), PTO-1449, Paper No(s). ☐ Interview Summary, PTO-413 ☐ Notice of Informal Patent Application, PTO-152 Notice of Reference(s) Cited, PTO-892 ☐ Other____ ☐ Notice of Draftsperson's Patent Drawing Review, PTO-948

Office Action Summary

U. S. Patent and Trademark Office PTO-326 (Rev. 9-97)

Part of Paper No. ____

Art Unit: 1614

The application is assigned to Procter & Gamble.

The common assignee has four (4) copending applications, namely Serial Nos. 10/019,029, 10/019,031, 10/019,038, and 10/019032 whose claims overlap in scope, presenting an issue of obviousness-type double patenting (one which can be overcome by filing acceptable terminal dis-claimers). Each claims oralcare actives in an (A) organosiloxane resin and/or admixture with fluid (B) diorganopoly siloxane –based polymers (C) volatile solvents, etc, and the actives (D) can be:.

(bleach) whitening actives, or pigments, opacifiers or colorants, etc.

The common assignee has six (6) issued U.S. patents, identified herein as Drechsler et al (I to VI), whose composition claims raise an issue of obviousness-type double patenting of the composition claims presented herein (one which can be overcome by filing acceptable terminal disclaimers), the patented commonly assigned Drechsler et al patents composition claims encompass the same (A), (B), and (C) with (D) pigment, opacifiers, or colorants, (even if not intended for oralcare). No weight is given in the USPTO for statements of intended use in composition claims.

The Hughes (I-V) patents teach whitening actives for dentures 1 and/or teeth in oralcare silicones, and Suchan et al teaches a tooth paint for coloring or tinting pigments onto teeth.

In Serial No. 10/019,029, there are 17 claims with composition claims 1 to 15 to (A),(B),(C),(D), (as noted above). The (D) actives, composition claims 4, 5, 14, 15 can be pigment/whitener pigment in claims 4, 14, whiteners in claims 5 and 15.

Art Unit: 1614

In Serial No. 10/019,031, there are 30 claims, with composition claims 1 to 28 to (A) (B) (C) (D), (as noted above), the (D) actives can be pigments coloring agents opacifiers claims 9, 23, or whiteners, claims 9, 11, 23, 25.

In Serial No. 10/019,032, there are 28 claims, with composition claims 1 to 24 to (A), (B), (C), (D), (as noted above). The (D) actives can be pigments, coloring agents, opacifiers, claims 4, 15 or whiteners, claims 4, 6, 15, 17.

In Serial No. 10/019,038, there are 26 claims, with composition claims 1 to 24 to (A), (B), (C), (D) (as noted above). The (D) actives can be pigments, coloring agents, opacifiers, claims 7, 8, 13 (etc), or whiteners, claims 10, 22.

Drechsler et al (I), I.S. 6,406,683, contains composition claims 1 to 4 to (A), (B), (C), (D) pigments.

Drechsler et al (II), I.S. 6,340,466, contains composition claims 1 to 20 to (A), (B), (C), (D) pigments (claim 3).

Drechsler et al (III), U.S. 6,139,823, contains composition claims 1 to 18 to (A), (B), (C), (D), pigments (claim 11).

Drechsler et al (IV), U.S. 6,071,503, contains composition claims 1 to 4 to (A) (B) (C) (D) (pigments).

Drechsler et al (V), U.S. 6,019,962, contains <u>only</u> method claims 1 to 12 wherein (A), (B), (C) is "applied," (not necessarily a lip cosmetic product applied to the lips, claim 2).

Art Unit: 1614

Suchan et al U.S. 4,032,627 describes a tooth paint whitening cosmetic wherein pigments, opacifiers, solvents, etc. are applied to teeth like nail polish, or correction fluid "white out".

Hughes (I) to (V) teeth encompassed species of tooth bleach whitening actives in silicone carriers, to remove stains from dentures and/or teeth.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1 to 28 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 to 30 of copending Application No. 10/019,031. Although the conflicting claims are not identical, they are not patentably distinct from each other because they overlap in scope.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 1 to 28 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 to 26 of

Art Unit: 1614

copending Application No. 10/019,038. Although the conflicting claims are not identical, they are not patentably distinct from each other because they overlap in scope.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 1 to 28 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 to 4 of U.S. Patent No. 6,406,683 in view of Suchan and Hughes (I-V) teaching the application to teeth or dentures of <u>pigments</u>, etc and bleaching actives (as noted above). It would be obvious therefrom to formulate oralcare (A), (B), (C), (D) with pigments and whiteners for teeth.

Claims 1 to 24 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 to 20 of U.S. Patent No. 6,340,466 in view of Suchan and Hughes (I-V) (same teachings, as noted above). Same reasons (as noted above).

Claims 1 to 24 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 to 18 of U.S. Patent No. 6,139,823 in view of Suchan and Hughes (I-V) (same teachings, as noted above).

Same reasons (as noted above).

Claims 1 to 24 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 to 4 of U.S. Patent No. 6, 071,503 in view of Suchan and Hughes (I-V) (same teachings, as noted above). Same reasons (as noted above).

Page 6

From the teaching of the references, it was apparent that one of ordinary skill in the art would have had reasonable expectation of success in producing the claimed invention. Therefore the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shep Rose whose telephone number is (703) 308-4609. The examiner can normally be reached on Monday, Tuesday and Thursday from 7:30 AM to 6 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

SHEP K. ROSE PRIMARY EXAMINER

Rose/LR October 28, 2002